IP Library Granted Patent US 10,188,783
Granted Patent B2
US 10,188,783 · App. 15/678,580 · Granted Jan 29, 2019

Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood

Inventors: Olle Larm (Bromma, SE); Tomas Bergstrom (Gotborg, SE)
Assignee: ExThera Medical Corporation
A61M1/3679A61K31/70A61M2202/0413A61M2202/203A61M2202/206Y02A50/411Y02A50/414Y02A50/473
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,188,783
App. No.
15/678,580
Granted
Jan 29, 2019
Kind
B2
Abstract

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

Claims (10)

1. A method for extracorporeal removal of a virus from a subject, said method comprising:

a) contacting said subject's whole blood with heparin immobilized on a solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said virus in said subject's whole blood sample to the heparin;

b) separating the whole blood from the solid substrate;

c) recovering said whole blood containing a reduced amount of said virus; and

d) reintroducing into said subject said whole blood containing a reduced amount of said virus.

2. The method of claim 1 , wherein said solid substrate comprises microparticles.

3. The method of claim 1 , wherein said solid substrate comprises fibers.

4. The method of claim 1 , wherein the material of said solid substrate is at least one member selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes.

5. The method of claim 1 , wherein said virus is selected from the group consisting of herpes simplex virus type 1, herpes simplex virus type 2, Influenza A virus, cytomegalovirus and human immunodeficiency virus.

6. The method of claim 5 , wherein said virus is selected from the group consisting of herpes simplex virus type I and herpes simplex virus type 2.

Priority Claims (1)
SE 05027503 · Dec 13, 2005 · national
Continuity (3)
Continuation 14873133 · Oct 1, 2015
Continuation 12086126
Related Publication 20170340803A1 · Nov 30, 2017